SciDiligence gives you the edge with strategic foresight, Bayesian modeling, and molecule-level intelligence. We fuse competitive insight with predictive analytics to show you where the market’s headed — and how to win there. Whether you’re developing drugs, striking deals, or making billion-dollar bets, we deliver the intelligence others miss.
Trusted by top law firms and government agencies, we provide expert scientific testimony and analysis on pharmacology, toxicology, public health, epidemiology, risk assessment, exposure assessment, and biostatistics. Our practice areas include toxic tort, medical malpractice (MEDMAL), toxicological death investigations, occupational and family drug and alcohol testing, DUI (including Standardized Field Sobriety Testing), Drug Recognition Expert (DRE), and Dram Shop cases.
We develop AI-powered platforms that reduce risk, accelerate safe therapies, and strengthen health outcomes—from early-stage drug safety decisions to clinical trial access in rural and underserved areas. Our innovations help biopharma teams de-risk R&D, optimize safety profiles, and align development with real-world needs—advancing innovation that saves time, lowers cost, and reaches more patients.
Federal agencies can now deny — or claw back — SBIR/STTR awards over undisclosed foreign ties: talent programs, overseas appointments, foreign entities, and foreign-linked investors. We screen your company, your people, and your planned disclosures against DoD, NSF, and NIH requirements before you submit, so you file cleanly and keep your award.
Heading to China, Russia, the Middle East, or another elevated-risk destination? Scientists and technical consultants are prime targets for elicitation, surveillance, and intellectual property theft abroad — and small businesses travel without the security teams large companies rely on. We brief you before you fly: device and data hygiene, digital conduct, in-country awareness, and local business customs, so you land prepared instead of exposed.
Identify Adverse Outcome Pathways (AOPs) and assays to screen and prioritize your drug products. Identify assays to run. Build weight of evidence arguments for waivers, to plan future preclinical studies, and identify potential clinical safety issues to monitor.
